⚕ GalenOps field
←

SITE015-0227

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE015 (POL) · Dr. Ito
consented 2022-11-23

AEs
8
Serious
1
Dropout signal
–

Adverse events

mild assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-12-28 (study day 27); relationship: Y

mild assessed

Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-01-16 (study day 46); relationship: N

moderate assessed

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-01-17 (study day 47); relationship: not assessed

moderate assessed

Grade 2 Alopecia — outcome: UNKNOWN; onset 2023-02-03 (study day 64); relationship: N

moderate assessed

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-02-22 (study day 83); relationship: not assessed

severe serious assessed

Grade 3 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-02-25 (study day 86); relationship: N; serious criteria: hospitalization

moderate assessed

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-03-10 (study day 99); relationship: N

mild assessed

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-03-13 (study day 102); relationship: N

Data queries

No data queries.